Financial Results for the quarter ended 30.06.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical reported revenue from operations of ₹1,513.47 lakhs for Q1 FY26, up about 19.9% from ₹1,262.08 lakhs in the same quarter last year. However, total expenses surged to ₹2,343.99 lakhs (vs ₹1,546.03 lakhs), driven mainly by higher raw material costs and direct manufacturing expenses. The company posted a net loss of ₹610.61 lakhs, much wider than the ₹136.33 lakhs loss in Q1 FY25, translating to a basic EPS of ₹(1.65). Loss before tax worsened to ₹814.80 lakhs from ₹281.70 lakhs, with ₹1.18 lakhs flagged as exceptional items related to provident fund damages. The statutory auditor issued an unqualified limited review report with no qualifications. On governance, the board appointed new internal, secretarial, and cost auditors for FY25-26, and Ms. Dolly Mandhan resigned as Company Secretary with Ms. Kumkum Bajaj replacing her.
Despite top-line growth, sharply rising costs have pushed the company deeper into losses, which is negative for shareholders. The widening quarterly loss, combined with cumulative annual losses exceeding ₹1,000 lakhs in FY25, signals ongoing operational stress that could weigh on the stock.